Cart
sales@molnova.com
Thalidomide-propargyl
CAS No. 2098487-39-7
Thalidomide-propargyl ( —— )
Catalog No. M27023 CAS No. 2098487-39-7
Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | Get Quote |
|
| 5MG | 58 | Get Quote |
|
| 10MG | 98 | Get Quote |
|
| 25MG | 178 | Get Quote |
|
| 50MG | 308 | Get Quote |
|
| 100MG | 461 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameThalidomide-propargyl
-
NoteResearch use only, not for human use.
-
Brief DescriptionThalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein.
-
DescriptionThalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-propargyl can be connected to the ligand for protein by a linker to form the IMiD containing PROTACs.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorHuman Endogenous Metabolite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2098487-39-7
-
Formula Weight312.3
-
Molecular FormulaC16H12N2O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1N(C2CCC(=O)NC2=O)C(=O)c2c1cccc2OCC#C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kawamoto M, et al. Biotransformation of (+/-)-2-methylcyclohexanone by fungi. Biotechnol Lett. 2008 Sep;30(9):1655-60.
molnova catalog
related products
-
H-9 hydrochloride
H-9 hydrochloride is a potent and competitive inhibitor of protein kinase C, cAMP-dependent protein kinase, and cGMP.
-
Diethylene glycol bi...
Diethylene glycol bis(p-toluenesulfonate) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
D-Glucosaminic acid
D-Glucosaminic Acid is a useful starting material for the synthesis of aldonic acids.
